

Serial No.: 10/789,758
Group Art Unit No.: 1645

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1 to 12: (Cancelled).

13. (Currently Amended) A composition for raising an immune response comprising a malaria antigen selected from the group of RTS,S and RTS,S* and an immunostimulatory CpG oligonucleotide wherein the composition does not contain a saponin.

14. (Cancelled).

15. (Cancelled).

16. (Currently Amended) A composition as claimed in claim 13 further comprising an aluminum salt, or 3 de-O-acylated monophosphoryl lipid A ~~or a saponin adjuvant~~.

17. (Previously presented) A composition as claimed in claim 13 wherein the oligonucleotide comprises two CpG dinucleotides.

18. (Previously presented) A composition as claimed in claim 13 wherein the CpG oligonucleotide is between 15-45 nucleotides in length.

19. (Previously presented) A composition as claimed in claim 13 wherein the CpG oligonucleotide comprises at least one phosphorothioate internucleotide bond.

20. (Currently Amended) A composition as claimed in claim 13 wherein the CpG oligonucleotide is selected from the group consisting of: SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, and SEQ ID NO:7.
~~oligonucleotides designated as WD1001, WD1002, WD1003, WD1004, WD1005, WD1006, and WD1007.~~

Serial No.: 10/789,758
Group Art Unit No.: 1645

21. (Previously presented) A method for the prevention or amelioration of plasmodium infection in a patient, comprising administering an effective amount of a composition of claim 13 to a patient.

22. (Previously presented) A method for the prevention or amelioration of plasmodium infection in a patient, comprising administering an effective amount of a composition of claim 16 to a patient.

Claims 23-24: (Cancelled).